Can I Take Vitamin B12 with Tresiba (Insulin Degludec)?

No Direct Interaction Exists Between Tresiba and Vitamin B12

Tresiba (insulin degludec) is a once-daily ultra-long-acting basal insulin analog approved for type 1 and type 2 diabetes. Vitamin B12 (cobalamin) is a water-soluble micronutrient absorbed in the terminal ileum through intrinsic-factor-mediated endocytosis. These two substances operate through entirely separate biological pathways.

Why the Routes Never Cross

Insulin degludec is injected subcutaneously and forms multi-hexamer chains in the subcutaneous depot before slowly dissociating into monomers that enter the bloodstream [3]. It binds insulin receptors on muscle, liver, and adipose tissue. Vitamin B12, by contrast, is taken orally, binds intrinsic factor in the stomach, and is absorbed in the distal ileum via cubilin receptors. Once in circulation, B12 serves as a cofactor for methionine synthase and methylmalonyl-CoA mutase.

What the Databases Say

Neither the FDA-approved Tresiba prescribing information nor the Natural Medicines Comprehensive Database lists vitamin B12 as an interacting substance with insulin degludec [4]. The Mayo Clinic drug interaction checker returns no results for this pair. There is no pharmacokinetic competition (no shared CYP450 metabolism, no shared transporter), and no pharmacodynamic opposition (B12 does not affect blood glucose or insulin sensitivity in a clinically meaningful way).

The Short Answer

You can take vitamin B12 at any time of day regardless of when you inject Tresiba. No dose adjustment to either agent is needed.

The Real Clinical Question: Metformin-Induced B12 Depletion

The reason this question surfaces so often is not about Tresiba itself. Most people on Tresiba for type 2 diabetes also take metformin. Metformin is the drug that depletes B12, and understanding that relationship matters more than the Tresiba-B12 pairing.

How Metformin Lowers B12

Metformin interferes with the calcium-dependent uptake of the intrinsic factor-B12 complex in the terminal ileum [1]. A 2010 randomized placebo-controlled trial (HOME trial, N=390) demonstrated that metformin 850 mg three times daily reduced serum B12 by 19% compared to placebo over 4.3 years and increased homocysteine by 5% [1]. The effect is dose-dependent and time-dependent.

Prevalence in the Real World

A 2016 meta-analysis of 29 studies (N=8,089) found that metformin use was associated with a 2.4-fold increased odds of B12 deficiency (OR 2.45, 95% CI 1.74-3.44) [5]. Prevalence of frank deficiency (serum B12 <200 pg/mL) ranged from 5.8% to 33% depending on metformin dose and duration. A cross-sectional NHANES analysis (N=1,621 adults with type 2 diabetes) found that 5.8% of metformin users had biochemical B12 deficiency versus 2.4% of non-users [6].

ADA Screening Recommendation

The American Diabetes Association's 2024 Standards of Care states: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy" [2]. This is a Grade B recommendation based on observational and randomized evidence.

Why B12 Deficiency Matters Specifically in Diabetes

B12 deficiency and diabetic peripheral neuropathy produce nearly identical symptoms: tingling, numbness, burning pain in the feet and hands, and impaired proprioception. Missing a treatable B12 deficiency while attributing symptoms entirely to diabetes is a common and consequential clinical error.

Overlapping Neuropathy Symptoms

A 2012 study published in Diabetes Care (N=550 type 2 diabetes patients on metformin) found that those with B12 deficiency had significantly worse neuropathy scores on the Toronto Clinical Neuropathy Score compared to B12-replete patients (P<0.001) [7]. The neuropathy was at least partially reversible with B12 supplementation in a subset of patients.

The Diagnostic Distinction

Serum B12 alone can miss early depletion. Methylmalonic acid (MMA) rises before serum B12 falls below the laboratory cutoff. An MMA level above 0.4 micromol/L in a patient with neuropathy symptoms should prompt B12 repletion regardless of the serum B12 number [8]. Homocysteine is a less specific marker but adds supporting evidence when elevated alongside MMA.

Clinical Consequence of Delayed Treatment

Prolonged B12 deficiency causes demyelination of the dorsal columns and peripheral nerves. If left untreated beyond 6-12 months, the neuropathy can become irreversible even after B12 repletion [8]. In a patient already at risk for diabetic nerve damage, this creates compounding injury to the same nerve fibers.

How to Supplement B12 While on Tresiba

Oral B12 supplementation is effective for most patients, including those with metformin-related malabsorption. High-dose oral B12 bypasses the intrinsic factor pathway through passive diffusion, which accounts for roughly 1% of the oral dose.

Oral vs. Intramuscular Repletion

A Cochrane systematic review found no significant difference in serum B12 normalization between high-dose oral cyanocobalamin (1,000-2,000 mcg/day) and intramuscular injections (1,000 mcg/month) for B12 deficiency [9]. Oral supplementation is preferred for adherence and cost unless the patient has pernicious anemia, ileal resection, or severe symptomatic deficiency requiring rapid correction.

Recommended Dosing

For prevention in metformin users: 1,000 mcg oral cyanocobalamin or methylcobalamin daily. For documented deficiency: 1,000-2,000 mcg daily for 8-12 weeks, then reassess serum B12 and MMA. The Endocrine Society and ADA do not specify a preferred form (cyanocobalamin vs. Methylcobalamin), though methylcobalamin is the bioactive coenzyme form and avoids the cyanide moiety [10].

Timing Relative to Tresiba

There is no pharmacological reason to separate B12 from your Tresiba injection. Tresiba can be injected at any time of day, and oral B12 can be taken with or without food. If you take metformin, some clinicians suggest taking B12 at a different meal than metformin to theoretically optimize absorption, but no controlled trial has validated this practice.

Monitoring Protocol for Patients on Tresiba Plus Metformin

A structured monitoring plan prevents B12 deficiency from developing silently. The following schedule reflects ADA and Endocrine Society guidance.

Baseline Labs

At the time metformin is started (or at the first visit if already established on metformin), obtain: serum B12, methylmalonic acid, complete blood count (CBC) with mean corpuscular volume (MCV), and homocysteine. MCV above 100 fL in a diabetic patient on metformin should raise suspicion for B12 or folate deficiency even if the B12 level is technically in range [2].

Annual Reassessment

Repeat serum B12 and MMA annually. If the patient develops new or worsening neuropathy symptoms, check immediately rather than waiting for the annual draw. The HOME trial showed that B12 decline on metformin is progressive, not a one-time drop, so ongoing surveillance is warranted [1].

When to Escalate

Refer to hematology or neurology if: serum B12 remains below 200 pg/mL despite 3 months of oral supplementation at 2,000 mcg/day, MMA fails to normalize, or neurological symptoms worsen. These patients may need intramuscular B12 loading (1,000 mcg daily for 7 days, then weekly for 4 weeks, then monthly) or evaluation for concurrent pernicious anemia [8].

Other Supplements Commonly Asked About with Tresiba

Patients who ask about B12 and Tresiba frequently also ask about other supplements. A brief orientation on the most common pairings.

Vitamin D

Vitamin D deficiency is prevalent in type 2 diabetes (estimated 60-80% in some cohorts) and may impair insulin secretion [11]. No interaction with insulin degludec exists. Supplementation with 1,000-4,000 IU daily of cholecalciferol (D3) is standard practice when 25-hydroxyvitamin D is below 30 ng/mL.

Magnesium

Hypomagnesemia occurs in 14-48% of patients with type 2 diabetes and may worsen insulin resistance [12]. Magnesium glycinate or citrate at 200-400 mg daily does not interact with Tresiba. Serum magnesium below 1.8 mg/dL warrants repletion.

Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) at 600 mg/day has shown modest benefit for diabetic neuropathy symptoms in the SYDNEY 2 trial (N=181) [13]. It may mildly lower blood glucose, so patients on Tresiba should monitor for hypoglycemia if adding ALA, though the effect is small.

What to Do If You Are Already Taking Both

If you are currently taking Tresiba and vitamin B12, there is nothing to change. Continue both as prescribed. Make sure your clinician knows about all supplements you take so they can interpret lab results in context (supplemental B12 will raise serum B12 levels and can mask a functional deficiency if MMA is not also checked).

Keep a record of your B12 dose and form. At your next diabetes visit, ask whether MMA has been checked in the past 12 months. If you are on metformin and have never had B12 or MMA measured, request it. Early detection of depletion prevents the one outcome nobody wants: irreversible neuropathy layered on top of diabetic nerve damage.

Patients on metformin for 4 or more years who have never supplemented B12 have a roughly 1-in-5 chance of biochemical deficiency [5].